Cervical priming before first trimester aspiration abortion: A single blind study comparing gemeprost 1 mg and prostaglandin E210mg pessaries

作者: I. Z. Mackenzie , Carrie Jackson , Eleanor McKinlay , Jean Millar

DOI: 10.3109/01443619009151257

关键词:

摘要: SummaryOne thousand and thirty patients have been studied in one of the largest single centre prospective random trials, assessing effects two prostaglandin vaginal pessaries upon cervical dilatation compliance during first trimester abortion by uterine aspiration under general anaesthetic. Gemeprost 1 mg inserted 1–4 hours before surgery produced marginally greater less operative blood loss than E2 10 pessaries, with a reduction distressing pre-operative side effects. No effect cervix was found if were for only 1–2 compared 3–4 hours. Postoperative later complications infrequent similar both preparations. are thus to be preferred this purpose.

参考文章(7)
I. Z. MacKenzie, Anna Fry, Prostaglandin E2 pessaries to facilitate first trimester aspiration termination. British Journal of Obstetrics and Gynaecology. ,vol. 88, pp. 1033- 1037 ,(1981) , 10.1111/J.1471-0528.1981.TB01693.X
P. Kajanoja, M. Mandelin, U.M. Mäkilä, O. Ylikorkala, C. Felding, C. Somell, A. Olund, Pedersen H., A Gemeprost vaginal suppository for cervical priming prior to termination of first trimester pregnancy. Contraception. ,vol. 29, pp. 251- 260 ,(1984) , 10.1016/S0010-7824(84)80005-0
H.T. Choo, S.M.M. Karim, Peggy Cheng, Extra-Amniotic Administration of Single Dose of 15 (S) 15 Methyl Prostaglandin E2 Methyl Ester for Pre-Operative Cervical Dilatation The Journal of The Asian federation of Obstetrics and Gynaecology. ,vol. 4, pp. 71- 73 ,(2010) , 10.1111/J.1447-0756.1973.TB00005.X
R. Nakano, H. Hata, K. Sasaki, M. Yamoto, THE USE OF PROSTAGLANDIN E1 ANALOGUE PESSARIES IN PATIENTS HAVING FIRST TRIMESTER INDUCED ABORTIONS British Journal of Obstetrics and Gynaecology. ,vol. 87, pp. 287- 291 ,(1980) , 10.1111/J.1471-0528.1980.TB04541.X
J.A. Stallworthy, A.S. Moolgaoker, J.J. Walsh, Legal abortion: a critical assessment of its risks. The Lancet. ,vol. 298, pp. 1245- 1249 ,(1971) , 10.1016/S0140-6736(71)90559-9